# A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.

> **NCT05644600** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 18 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** AZD5055

## Key facts

- **NCT ID:** NCT05644600
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-26
- **Primary completion:** 2023-07-17
- **Final completion:** 2023-07-17
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** The study was terminated as no drug-drug interactions were observed in Part-A of the study and therefore Part-B of the study was not required as per protocol.
- **Last updated:** 2024-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05644600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05644600, "A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05644600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*